Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bvlgari, the Italian luxury brand, has today announced plans to support research into COVID-19 and vaccine development at Oxford University.

© Sean Elias

The new relationship comes as part of the brand’s commitment to better preventing pandemics now and in the future, through philanthropic donations. This gift will support Oxford research in two key areas; by purchasing boundary-pushing scientific equipment that will help to speed up vaccine development, and financing the studies of some of the world’s most talented researchers engaged in the field.

The collaboration was announced during a live webinar hosted by Jean-Christophe Babin, President and CEO of Bvlgari and Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, University of Oxford.

Professor Sarah Gilbert, Professor of Vaccinology at the University of Oxford, said: 'For us to continue to make world-leading advances against infectious diseases we need more excellent young scientists to join the field of vaccinology, and access to the most up to date equipment for our laboratories. This generous gift from Bvlgari addresses both of these needs, and will continue to have an impact for many years to come.'

Read the full story on the University of Oxford website

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.